The challenge of our time
The looming reality of health inequity and how healthcare communicators can help fight against it
New Search
If you are not happy with the results below please do another search
Search
50 search results for:
AstraZeneca and Daiichi Sankyo’s Enhertu becomes first HER2-directed therapy for NSCLC
/in R&D, TherapeuticsAstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu has been approved by the U.S. Food and Drug Administration as the first HER2-directed medicine for patients with HER2-mutant metastatic NSCLC, a particularly lethal form of the disease.
Drugmakers’ shares stabilize after Zantac litigation slump
/in Business, TherapeuticsShares in GSK, Sanofi, Haleon, and Pfizer began to recover on Friday after the companies said that nothing material had changed regarding U.S. litigation focused on heartburn drug Zantac.
Biotech stocks pin bounce back hopes on M&A boost
/in R&D, TherapeuticsPlunging valuations have made biotech companies tempting acquisition targets for cash-rich Big Pharma and a flurry of deals is just what the battered sector needs to turn a corner.
Blood pressure drug terazosin shows promise in ALS treatment
/in R&D, Therapeutics“Our work shows that terazosin is protective of motor neuron cell death in multiple models of MND [motor neuron disease], making it an exciting new potential therapy,” says Helena Chaytow, the study’s first author and senior postdoctoral researcher at the University of Edinburgh.
Got milk? It may do the microbiome – and patients – good
/in R&D, TherapeuticsIn a first, Prolacta Bioscience recently published a proof of concept study showing that components of human breast milk can treat the adult microbiome without antibiotics.
Abbott to add 1,000 jobs in $450 million Irish investment
/in Business, TherapeuticsConfirming the $450 million investment, Abbott’s senior vice-president for diabetes care, Jared Watkin, told the Irish Times that choosing Ireland for its increased production of devices that monitor glucose levels made strategic sense.
J&J to end global sales of talc-based baby powder
/in Marketing & AdvertisingJohnson & Johnson will stop selling talc-based baby powder globally in 2023, the drugmaker said on Thursday, more than two years after it ended U.S. sales of a product that drew thousands of consumer safety lawsuits.
Roche announces U.S. FDA approval of Xofluza to treat influenza in children aged five years and older
/in TherapeuticsXofluza is the first and only single-dose oral medicine for the treatment of influenza to be approved in the United States for children as young as five years of age. The FDA also approved the drug to prevent influenza in children aged five years and older following contact with an infected person.
Novartis reports Zolgensma caused two deaths from liver failure
/in TherapeuticsThe two fatal cases of acute liver failure took place in Russia and Kazakhstan after 5 to 6 weeks of Zolgensma infusion and about 1-10 days following the initiation of corticosteroid taper, according to the company.
